Preventix

Austria's YGION Biomedical is dedicated to turning personalized cancer immunotherapy into a viable option.

At Immitra Bio, we are developing a unique genetic medicine platform that combines two of the most powerful biomedical technologies: hematopoietic stem cells (HSCs) and CRISPR-Cas9 gene editing. Our novel technique allows for precise and long-lasting gene alterations within blood stem cells, resulting in transformational treatments for uncommon diseases with significant unmet medical needs.

ALZpath is a biotech organization that offers innovative diagnostic options for Alzheimer's disease.

Reme-D is a cutting-edge technology company that has patented technology, which is revolutionizing healthcare in areas with limited resources by providing cost-effective and efficient disease testing systems. This ensures that everyone has equal access to essential medical diagnostics.

Brenus Pharma is a platform that uses allogeneic techniques to create immune therapy with the goal of activating the patient's immune system to combat cancer and reduce resistance to treatment.

Trellis Bioscience develops a technology platform for cellular informatics. The company's technology has applications in the discovery and production of therapeutic monoclonal antibodies. Its cell biology platform provides a direct readout at the single cell level for monitoring activity of diverse cell types and quantifying the impact of potential therapeutic interventions. The company is based in San Francisco, California.

NOUS is a biotech startup working on developing a new era of ingredients for Food&Beverage and Nutraceutical Market. Our first product is Mindave, a caffeine alternative that enhances cognitive and physical performance, improving memory, concentration and reflexes without causing the typical adverse effects of caffeine such as blood pressure spikes or tachycardia, and improves gastrointestinal well-being. A recent functional study demonstrated the effectiveness of Mindave on cognitive function, showing benefits even superior to caffeine. Worldwide, 709 million people should avoid caffeine due to gastrointestinal or heart problems. However, there is currently no viable, healthy and 100% natural alternative on the market to enable everyone to face each day with full energy. In addition, the rapid changes in consumer needs and market trends pose a major challenge to medium and large companies who are unable to respond quickly to the constant new product launches. We are targeting companies with a clear health mission, enabling us to help consumers live better. Our ideal customers are beverage and food companies for developing new functional products, ingredient companies for exponential distribution through consolidated networks, and fitness companies. Being selected for the Plag&Play accelerator programme in San Francisco has opened the door to the American market and after filling the international patent in December 2023, we started the commercialisation in January 2024. To date we have +11 LOIs from customers, 5 POCs underway with ITA and US companies, 1 contract for product development consultancy with a startup and 1 ingredient company selling Mindave as part of their portfolio, allowing us to benefit from their network. We are firm believers in the link between human health and the environment’s health. With Mindave, we estimate -40% of water waste, -30% of deforestation and -30% of CO2 emissions at full production compared to coffee farming. Our focus on sustainable innovation leads us to develop new by-products from upcycling every year until we reach zero waste by 2027. We forecast the development of at least 5 products by 2027. Inspired by nature, we aim to innovate the F&B sector while reducing environmental impact.

AdvanCell is a company that focuses on developing innovative cancer treatments using alpha-emitting isotopes attached to molecules, which can deliver targeted radiation to tumors at the molecular level. This approach enables healthcare providers to offer safe and efficient treatment options for various types of cancer.

Lyora Therapeutics develops genetic medicines for inherited retinal diseases that currently have no treatment.

ArcGen Bioscience is a biopharmaceutical development company

Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of hard-to-treat disease in a unique and transformative approach to drug discovery and development. Alchemab takes an unbiased and function-first approach using three complementary processes and cutting-edge technologies to identify naturally protective antibodies. Alchemab’s engine is enabled through collaborations with patient representative groups and biobanks around the world with whom we partner to further our understanding of disease.

Wugen is a developer of a novel CAR-T therapy platform intended for T-Cell Malignancies.The company's state-of-the-art gene editing technologies and cutting-edge Car-T cell therapy address some of the challenges that have limited the clinical development of allogeneic Car-T cells, enabling patients aid in the treatment of cancer.